Link to this page
National Cancer Institute Thesaurus
Last uploaded:
July 2, 2026
| Id | http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C97947
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C97947
|
|---|---|
| Preferred Name | Certolizumab |
| Definitions |
A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis.
|
| Synonyms |
Certolizumab
CERTOLIZUMAB
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| label | Certolizumab
|
|---|---|
| prefixIRI | Thesaurus:C97947
|
| code | C97947
|
| DEFINITION | A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis.
|
| PDQ_Open_Trial_Search_ID | 760457
|
| Contributing_Source | FDA
|
| NCI_Drug_Dictionary_ID | 760457
|
| FULL_SYN |
Certolizumab
CERTOLIZUMAB
|
| NCI_META_CUI | CL430555
|
| FDA_UNII_Code | G6ADW90R16
|
| Preferred_Name | Certolizumab
|
| type | |
| subClassOf | |
| PDQ_Closed_Trial_Search_ID | 760457
|
| Concept_In_Subset | |
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |